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All text descriptions are accurate and reported results were calculated correctly using the formula above.DOI of original article: http://dx.doi.org/10.1016/j.jval.2010.08.001Erratum
In: Hudgens S, Schüler R, Hunsche E, Leist T. Psychometric validation of the Fatigue Symptoms and Impacts Questionnaire–Relapsing Multiple
Sclerosis (FSIQ-RMSTM). Value in Health 2015;18:A26.
The title of the published abstract contained incorrect rendering of the en-dash and trademark symbols, and there were errors in capitalization and
superscripting. The corrected abstract reads:
Psychometric validation of the Fatigue Symptoms and Impacts Questionnaire–Relapsing Multiple Sclerosis (FSIQ-RMSTM)
Hudgens S1, Schüler R2, Hunsche E2, Leist T3
1Clinical Outcomes Solutions, Tucson, AZ, USA, 2Actelion Pharmaceuticals Ltd., Allschwil, Switzerland, 3Thomas Jefferson University Hospital, Philadelphia, PA, USA
OBJECTIVES: Fatigue is an important symptom for multiple sclerosis (MS) patients. Qualitative research supported initial content validity of the FSIQ-
RMS™,1 the ﬁrst patient-reported outcome (PRO)measure of fatigue in relapsing (R)MSdeveloped according to the 2009 FDA PROguidance. To conﬁrm
appropriateness, validity, and reliability of the FSIQ-RMS, further psychometric analyses were required.METHODS: The FSIQ-RMS™with 9 Symptom
items (daily recall period, 1 subdomain) and 14 Impact items (weekly recall period, 3 subdomains) was administered over 3 months (three 7-day
intervals) in a multicenter, non-interventional, US-based, IRB-approved study to adult patients with different RMS subtypes (relapsing remitting,
secondary progressive, progressive relapsing) and a subset of matched healthy controls (week 1 only). Data analyses included: item response and
dimensionality; content and construct validity; internal consistency and test-retest reliability; aswell as attribution of fatigue to RMS. Evaluationswere
supported by those from a cross-sectional, multicenter study, in which RMS patients completed the FSIQ-RMS™ Symptoms domain. RESULTS: The
psychometric validation study included 164 RMS patients (mean age 45 [range 19–65] years; 76% female) and 74 controls (40 [18–65] years; 73% female).
Two redundant Symptom itemswere deleted, leaving 7; Impact itemswere unchanged. A 0–100 scoring algorithmwas developed for the FSIQ-RMS™
(sub)domains. Internal consistency (Cronbach’s alpha 0.87–0.97) and test-retest reliability (intraclass correlation coefﬁcient [ICC] 0.92–0.95) of all (sub)
domains exceeded pre-speciﬁed thresholds (alpha40.70; ICCZ0.70). The Symptoms domain discriminated along the symptom-severity continuumof
RMS patients and between patients and healthy controls. Patients were able to attribute fatigue-related symptoms to RMS (14-point difference vs.
controls; Po0.0001). Findings were supported by those from the cross-sectional study (N¼154). CONCLUSIONS: Content andmeasurement validity of
the revised ﬁnal FSIQ-RMS™ were conﬁrmed. Responsiveness of the PRO will be evaluated in a Phase III trial. 1Value Health 2014;17:A195-6.DOI of original article: http://dx.doi.org/10.1016/j.jval.2015.03.160
